The Role of Isoproterenol in Pulmonary Artery Hypertension of Unknown Etiology (Primary) Eulo Lupi-Herrera, M.D., David Bialostozky, M.D., Angel Sobrino, M.D. CHEST Volume 79, Issue 3, Pages 292-296 (March 1981) DOI: 10.1378/chest.79.3.292 Copyright © 1981 The American College of Chest Physicians Terms and Conditions
FIGURE 1 Clinical and ECG findings, case 4, asymptomatic. CHEST 1981 79, 292-296DOI: (10.1378/chest.79.3.292) Copyright © 1981 The American College of Chest Physicians Terms and Conditions
FIGURE 2 Changes in systolic pulmonary artery pressure (SPAP) observed after (A) infusion or sublingual administration of isoproterenol. CHEST 1981 79, 292-296DOI: (10.1378/chest.79.3.292) Copyright © 1981 The American College of Chest Physicians Terms and Conditions
FIGURE 3 Relationship between mean pulmonary artery pressure (PAP) and cardiac index (CI) before (B) and after (A) isoproterenol. Significant p values obtained. CHEST 1981 79, 292-296DOI: (10.1378/chest.79.3.292) Copyright © 1981 The American College of Chest Physicians Terms and Conditions
FIGURE 4 Relationship between cardiac index (CI) and pulmonary arteriolar resistance (PAR) before (B) and after (A) infusion or sublingual administration of isoproterenol. Decrease of PAR normal or close to normal in cases 4 and 6. CHEST 1981 79, 292-296DOI: (10.1378/chest.79.3.292) Copyright © 1981 The American College of Chest Physicians Terms and Conditions